{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:30:04Z","timestamp":1779903004683,"version":"3.53.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":613,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>There is a lack of specific studies assessing the impact of natriuretic peptide monitoring in the post-discharge management of patients with heart failure (HF) and preserved ejection fraction (HFpEF), throughout the vulnerable phase following acute HF hospitalization. The NICE study aims to assess the clinical benefit of incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) into the post-discharge management of HFpEF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Individuals admitted with HFpEF (left ventricular ejection fraction &amp;gt;50%) were included in a multicentre randomized controlled study employing an open-label design with event blinding (NCT02807168). Upon discharge, 157 patients were randomly allocated to either NT-proBNP monitoring (n\u2009=\u200979) or no access to NT-proBNP (control group, n\u2009=\u200978) during pre-scheduled visits at 2, 4 and 12\u2009weeks. Clinical endpoints were evaluated at 6\u2009months. The primary endpoint of HF rehospitalizations occurred in 12.1% patients, without significant differences observed between the NT-proBNP monitoring group (12.8%) and the control group (11.4%) (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.47\u20132.81, p\u2009=\u20090.760). Regarding secondary endpoints, the NT-proBNP monitoring group demonstrated a significantly lower risk of death (1.3% vs. 10.1%; HR 0.12, 95% CI 0.02\u20130.98; p\u2009=\u20090.048), whereas non-HF hospitalizations (12.8% vs. 19.0%, p\u2009=\u20090.171) and any adverse clinical event (26.9% vs. 36.7%, p\u2009=\u20090.17) did not reach statistical significance [Correction added on 29 April 2024, after first online publication: In the preceding sentence, \u201c95% CI 0.02 - 0.09\u201d has been corrected to \u201c95% CI 0.02 - 0.98; p = 0.048\u201d in this version.]. Awareness of NT-proBNP levels were associated with higher doses of diuretics and renin\u2013angiotensin system inhibitors (angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers) in the NT-proBNP monitoring group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Post-discharge monitoring of NT-proBNP in HFpEF patients did not exhibit an association with reduced rates of HF hospitalization in this study. Nonetheless, it appears to enhance global clinical management by optimizing medical therapies and contributing to improved overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3222","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T04:30:06Z","timestamp":1712896206000},"page":"776-784","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction \u2013 A Randomized Trial: The NICE Study"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-9540","authenticated-orcid":false,"given":"Domingo A.","family":"Pascual-Figal","sequence":"first","affiliation":[{"name":"Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla , Murcia ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"CIBERCV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Hern\u00e1ndez-Vicente","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pastor-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla , Murcia ,","place":["Spain"]},{"name":"CIBERCV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mart\u00ednez-Sell\u00e9s","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Gregorio Mara\u00f1\u00f3n, Universidad Europea, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-9925","authenticated-orcid":false,"given":"Eduard","family":"Sol\u00e9-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Clinic , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Alvarez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garc\u00eda-Pav\u00eda","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Madrid \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Varela-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Cl\u00ednico Universitario de Santiago , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Luis","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Clinico de Salamanca-IBSAL, Universidad de Salamanca , Salamanca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Delgado","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Noguera-Velasco","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"CIBERCV , Madrid ,","place":["Spain"]},{"name":"Heart Institute, Hospital Universitari Germans Trias i Pujol , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"NICE study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"2026010913074916800_ejhf3222-bib-0001","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0003","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026010913074916800_ejhf3222-bib-0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913074916800_ejhf3222-bib-0005","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jama.2010.533","article-title":"Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure","volume":"303","author":"Hernandez","year":"2010","journal-title":"JAMA"},{"key":"2026010913074916800_ejhf3222-bib-0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15420\/cfr.2018.26.1","article-title":"Natriuretic peptides in chronic heart failure","volume":"5","author":"Brunner-La Rocca","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026010913074916800_ejhf3222-bib-0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"2026010913074916800_ejhf3222-bib-0008","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0009","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"2026010913074916800_ejhf3222-bib-0010","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","article-title":"NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"},{"key":"2026010913074916800_ejhf3222-bib-0011","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026010913074916800_ejhf3222-bib-0012","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/eurheartj\/ehad335","article-title":"NT-proBNP and high intensity care for acute heart failure: The STRONG-HF trial","volume":"44","author":"Adamo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913074916800_ejhf3222-bib-0013","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","article-title":"Management of chronic heart failure guided by individual N-terminal proB-type natriuretic peptide targets: Results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study","volume":"56","author":"Eurlings","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0014","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurheartj\/ehq509","article-title":"Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur Heart J"},{"key":"2026010913074916800_ejhf3222-bib-0016","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026010913074916800_ejhf3222-bib-0017","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2018.04.049","article-title":"Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis","volume":"263","author":"Khan","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026010913074916800_ejhf3222-bib-0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-018-0776-8","article-title":"B-type natriuretic peptide-guided therapy for heart failure (HF): A systematic review and meta-analysis of individual participant data (IPD) and aggregate data","volume":"7","author":"Pufulete","year":"2018","journal-title":"Syst Rev"},{"key":"2026010913074916800_ejhf3222-bib-0020","article-title":"B-type natriuretic peptide-guided treatment for heart failure","volume":"12","author":"McLellan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010913074916800_ejhf3222-bib-0021","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/eurjhf\/hft076","article-title":"N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: Findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)","volume":"15","author":"Maeder","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026010913074916800_ejhf3222-bib-0022","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/ejhf.401","article-title":"Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials","volume":"17","author":"Brunner-La Rocca","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026010913074916800_ejhf3222-bib-0023","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026010913074916800_ejhf3222-bib-0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.recesp.2023.05.006","article-title":"Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure","volume":"77","author":"Santas","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026010913074916800_ejhf3222-bib-0025","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/eurheartj\/ehad356","article-title":"Making STRONGer the transition phase: Personalized GDMT through NT-proBNP monitoring","volume":"44","author":"Bayes-Genis","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913074916800_ejhf3222-bib-0026","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/776\/65514391\/eurjhf_26_4_776.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/776\/65514391\/eurjhf_26_4_776.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:38Z","timestamp":1767982178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/4\/776\/8328873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3222","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}